Details

Autor(en) / Beteiligte

• Rhanine, Yasmine
• Bonnefoi, Hervé
• Goncalves, Anthony
• Debled, Marc
• Le Moulec, Sylvestre
• Bonichon, Nathalie
• Macgrogan, Gaetan
• Arnedos, Monica
• Dubroca-Dehez, Bénédicte
• Grellety, Thomas

Titel

Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

Ist Teil von

• Breast (Edinburgh), 2024-02, Vol.73, p.103667-103667, Article 103667

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials. •Antiandrogen efficacy in real-life are in line with clinical trials in AR + TNBC.•Some AR + TNBC patients derive long-term clinical benefit for antiandrogen.•Antiandrogens efficacy biomarkers are still warranted.